Nagel Jens, Greco Sergio, Parsons Chris G, Flik Gunnar, Tober Carsten, Klein Kai-Uwe, Danysz Wojciech
Merz Pharmaceuticals GmbH, Frankfurt/Main, Germany.
Brains On-Line B.V., Groningen, The Netherlands.
Pharmacol Rep. 2015 Jun;67(3):624-30. doi: 10.1016/j.pharep.2015.01.004. Epub 2015 Jan 22.
To verify relation between brain free levels, receptor occupancy in vivo and in vitro affinity at the target for mGluR5 negative allosteric modulator (NAM) MTEP.
We evaluated plasma and brain extra-cellular fluid (ECF) concentration of MTEP at behaviourally active dose (5mg/kg) using in vivo microdialysis. These values were compared it to the affinity in vitro (receptor binding and FLIPR) and to receptor occupancy in vivo. Another, related substance, MPEP was used for comparison.
MTEP and MPEP respectively inhibited mGluR5 receptors function in vitro with an affinity of 25.4 and 12.3 nM respectively. Accordingly peak ECF (extracellular fluid) levels were 1.3 and 0.14 μM, and peak total plasma levels were 7-11 and 2.6 μM. The ED50 for in vivo receptor occupancy was for both agents in the range of 0.8-0.7 mg/kg.
At behaviourally active dose MTEP produced complete mGluR5 receptor occupancy but over 50 times higher ECF concentrations than affinity for mGluR5 receptor in vitro. This difference is seems lower for other mGluR5 NAM compounds such as MPEP. A possibly explanation could be different distribution in body compartments of both agents leading to errors of estimation with the microdialysis technique or different pharmacological activity at the receptor.
验证代谢型谷氨酸受体5(mGluR5)负变构调节剂(NAM)MTEP的脑游离水平、体内受体占有率与靶点体外亲和力之间的关系。
我们使用体内微透析技术,评估了行为活性剂量(5mg/kg)下MTEP的血浆和脑细胞外液(ECF)浓度。将这些值与体外亲和力(受体结合和荧光成像板读数器)以及体内受体占有率进行比较。另外,使用相关物质MPEP进行对比。
MTEP和MPEP在体外分别以25.4和12.3 nM的亲和力抑制mGluR5受体功能。相应地,ECF(细胞外液)峰值水平分别为1.3和0.14 μM,血浆总峰值水平分别为7 - 11和2.6 μM。两种药物的体内受体占有率ED50均在0.8 - 0.7 mg/kg范围内。
在行为活性剂量下,MTEP可使mGluR5受体完全被占据,但ECF浓度比其对mGluR5受体的体外亲和力高50倍以上。对于其他mGluR5 NAM化合物(如MPEP),这种差异似乎较小。一种可能的解释是,两种药物在身体各腔室中的分布不同,导致微透析技术的估计误差,或者在受体上具有不同的药理活性。